AIMT Aimmune Therapeutics, Inc. gains 16% Jan 9, 2020

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.http://www.priceseries.com/trade/AIMT-Aimmune-Therapeutics-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019120320200109.html